Phase I Study of the Administration of Low-dose Perioperative Human Atrial Natriuretic Peptide in Patients With Resectable Colorectal Cancer.
Adult
Aged
Atrial Natriuretic Factor
/ administration & dosage
Biomarkers
Colorectal Neoplasms
/ complications
Electrocardiography
Female
Heart Failure
/ diagnosis
Humans
Male
Middle Aged
Neoplasm Staging
Perioperative Care
Postoperative Complications
/ diagnosis
Symptom Assessment
Treatment Outcome
Colorectal cancer
feasibility
human natriuretic peptide
prevention of metastasis
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
14
02
2020
revised:
20
02
2020
accepted:
25
02
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
20
9
2020
Statut:
ppublish
Résumé
The aim of this single center, non-randomized, open-label, uncontrolled, interventional trial was to determine the feasibility of continuous administration of low-dose human atrial natriuretic peptide (hANP) perioperatively during curative operation for colorectal cancer patients without history of acute heart failure. The study included three males and two females ranging from 27 to 70 years old. Continuous intravenous injection of hANP solution was started before surgery. The primary endpoint was safety of hANP administration, and the secondary endpoints were perioperative changes in ANP, b-type natriuretic peptide, electrocardiogram (ECG), and lung function. The American Society of Anaesthesiologists physical status was 1, 2, and 3 in three, one, and one patient, respectively. Grade 2 hypotension was observed in one case. No marked changes were observed between pre- and post-operation in all cases. Perioperative low-dose hANP administration is feasible and safe in patients with curative colorectal cancer.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The aim of this single center, non-randomized, open-label, uncontrolled, interventional trial was to determine the feasibility of continuous administration of low-dose human atrial natriuretic peptide (hANP) perioperatively during curative operation for colorectal cancer patients without history of acute heart failure.
PATIENTS AND METHODS
METHODS
The study included three males and two females ranging from 27 to 70 years old. Continuous intravenous injection of hANP solution was started before surgery. The primary endpoint was safety of hANP administration, and the secondary endpoints were perioperative changes in ANP, b-type natriuretic peptide, electrocardiogram (ECG), and lung function.
RESULTS
RESULTS
The American Society of Anaesthesiologists physical status was 1, 2, and 3 in three, one, and one patient, respectively. Grade 2 hypotension was observed in one case. No marked changes were observed between pre- and post-operation in all cases.
CONCLUSION
CONCLUSIONS
Perioperative low-dose hANP administration is feasible and safe in patients with curative colorectal cancer.
Identifiants
pubmed: 32878821
pii: 40/9/5301
doi: 10.21873/anticanres.14536
doi:
Substances chimiques
Biomarkers
0
Atrial Natriuretic Factor
85637-73-6
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5301-5307Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.